Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.
The company said the disposal of these two businesses is part of a strategy to focus entirely on the molecular diagnostics market.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
The claim, enabling streamlined screening of pooled samples, follows updated industry recommendations for Zika virus screening in the US blood supply.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
A panel at the Biology of Genomes meeting discussed the ethical, legal, and social ramifications of germline gene editing.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
The revenue increase was primarily driven by collaborative development services activities with partners including Qiagen.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
BC Platforms will incorporate Sentieon's next-generation sequencing data-processing software into its integrated genomics and clinical data products.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The company said 677 of its GPS Cancer commercial tests were ordered in Q1 2018, up from 606 in Q4 2017.
VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.
The higher revenues were driven by a 38 percent increase in product sales, which include the company's Epi proColon blood-based colorectal cancer screening test.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.
The revenue growth was driven by an increase in collaboration revenues, which offset declines in product sales and lab services revenues.
Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.
Genetic genealogy has led to an arrest in another cold case, dating back to 1987.
In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.
Wired reports that 23andMe is trying to bolster its outside collaborations.